ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new client wins are driving growth, and the group hopes to report initial vaccine results, in partnership with Netherlands-based LiteVax, by November of this year.
ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates pre-clinical coronavirus vaccine study
Quick facts: ImmunoPrecise Antibodies Ltd
Price: 2.44 CAD
Market Cap: $195.14 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...FOR OUR FULL DISCLAIMER CLICK HERE